People: Dendreon Corp (DNDN.OQ)
Dr. Mark W. Frohlich, M.D., is Executive Vice President - Research and Development, Chief Medical Officer of Dendreon Corporation, since March 2011. Prior to that time served as Executive Vice President for Clinical Affairs and Chief Medical Officer from December 2010 to March 2011. Previously, Dr. Frohlich served as Senior Vice President for Clinical Affairs and Chief Medical Officer from January 2008 to December 2010. Dr. Frohlich also served as Vice President of Clinical Affairs from April 2006, and from August 2005, served as Senior Medical Director. Prior to joining Dendreon, Dr. Frohlich was Vice President and Medical Director at Xcyte Therapies, Inc., a biotechnology company, from October 2001 to July 2005. From 1998 to 2001, Dr. Frohlich was a member of the faculty of the University of California at San Francisco where he served as an assistant professor in the Division of Hematology/Oncology. Dr. Frohlich received a Bachelor of Science in electrical engineering and economics from Yale University and an M.D. from Harvard Medical School.
|Total Annual Compensation, USD||Long-Term Incentive Plans, USD||All Other, USD||Fiscal Year Total, USD|